Catalyst Biosciences Inc reports results for the quarter ended in March - Earnings Summary

Gyre Therapeutics

16/05/2023 06:44

* Catalyst Biosciences Inc  CBIO.OQ  reported quarterly
adjusted
earnings of 1 cent​​ per share for the quarter ended in March.
The lone analyst forecast for the quarter was for a loss of 7
cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * The mean earnings estimate of analysts had risen by
about 30% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Catalyst Biosciences Inc shares had risen by 6.3% this
quarter and lost 32.6% so far this year.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
16 at 05:44 a.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.07          0.01           Beat
 Dec. 31 2022      -0.10                         
 Sep. 30 2022      -0.10          -0.16          Missed
 Jun. 30 2022      -0.24          -0.18          Beat